Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
130.34
+1.72 (1.34%)
At close: Nov 4, 2026, 4:00 PM EST
131.11
+0.77 (0.59%)
Pre-market: Nov 5, 2026, 7:23 AM EST

Halozyme Therapeutics Revenue

Halozyme Therapeutics had revenue of $481.00M in the quarter ending June 30, 2026, with 47.67% growth. This brings the company's total for the last twelve months to $1.66B, up 41.15% year-over-year. In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth. That makes Halozyme Therapeutics the 5,612th largest company in the world by revenue and 1,425th in the United States.

Revenue (ttm)
$1.66B
Revenue Growth
+41.15%
P/S Ratio
8.89
Revenue / Employee
$3,933,187
Employees
423
Market Cap
14.79B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Royalties 867.84M 62.1%
  • Sales of Proprietary Products 194.61M 13.9%
  • Revenue Under Collaborative Agreements 152.33M 10.9%
  • Sales of Bulk rHuPH20 133.02M 9.5%
  • Sales of Device Partnered Products 48.81M 3.5%

By Geography

Chart
  • United States 822.98M 58.9%
  • Switzerland 276.41M 19.8%
  • Belgium 217.52M 15.6%
  • Japan 46.37M 3.3%
  • All Other Foreign Countries 33.33M 2.4%
Fiscal year ended Dec 31, 2025 See the full Halozyme Therapeutics breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.40B381.29M37.55%
Dec 31, 20241.02B186.07M22.44%
Dec 31, 2023829.25M169.14M25.62%
Dec 31, 2022660.12M216.81M48.91%
Dec 31, 2021443.31M175.72M65.67%
Dec 31, 2020267.59M71.60M36.53%
Dec 31, 2019195.99M44.13M29.06%
Dec 31, 2018151.86M-164.75M-52.04%
Dec 31, 2017316.61M169.92M115.84%
Dec 31, 2016146.69M11.63M8.61%
Dec 31, 2015135.06M59.72M79.28%
Dec 31, 201475.33M20.54M37.47%
Dec 31, 201354.80M12.47M29.47%
Dec 31, 201242.33M-13.76M-24.54%
Dec 31, 201156.09M42.46M311.67%
Dec 31, 201013.62M-47.19K-0.35%
Dec 31, 200913.67M4.91M55.99%
Dec 31, 20088.76M4.96M130.66%
Dec 31, 20073.80M2.82M287.02%
Dec 31, 2006981.75K854.54K671.76%
Dec 31, 2005127.21K--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.